Nora Therapeutics
Palo Alto
About Nora Therapeutics
Nora Therapeutics is a specialty biopharmaceutical company focused on developing therapeutics to address clinical unmet needs in reproductive medicine. Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF) procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $36.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2014)
- Website: noratherapeutics.com
- Phone: (650)688-0818
Industries & Categories
Biotechnology, Health Care, Medical Device
Canonical: https://fsome.com/organization/nora-therapeutics-2446128 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.